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Purpose/Objective: Hippocampal-avoiding whole brain 
radiotherapy (HA-WBRT) for multiple brain metastases may 
prevent treatment-related cognitive decline, compared to 
standard WBRT. Reduction in hippocampal volume over time 
has been shown to be significantly related to decline in 
memory and learning. This study aims at exploring brain 
volume changes after whole brain radiotherapy with 
hippocampal avoidance (HA-WBRT). 
Materials and Methods: 22 patients who had been assigned 
to HA-WBRT following clinical indication received MRI before 
and up to 19 months after treatment (Mean = 5 months). 
Observer-independent, automated volumetry of the 
hippocampi, the lateral ventricles, and the whole brain was 
performed on 77 MRI data sets using Matlab and statistical 
parametric mapping (SPM8). Longitudinal volumes have been 
tested for significant brain changes after HA-WBRT. Linear 
mixed models were computed with regional volumes as 
dependent variables and predictor variable time with random 
intercepts and slopes for time across subjects and variance 
components as covariance structure (controlling for age). 
Volume change rates after RT have been calculated for each 
region. 
Results: At the group level, hippocampal [-0.02 ml (-0.19%) 
per month] and whole brain volumes [-2.03 ml (-0.19%) per 
month] showed decreases which did not reach significance. 
By contrast, the lateral ventricles significantly expanded [p < 
0.0001; +1.2 ml (3.6%) per month (43% per year)]. 
Conclusions: In this pilot study we observed no significant 
hippocampal atrophy after HA-WBRT. The lateral ventricles, 
however, expanded after treatment, indicating cerebral 
atrophy at a higher rate than reported in the literature on 
healthy subjects. While brain tissue degeneration seems to 
occur in this group of patients, hippocampal tissue is spared 
from this process. 
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Purpose/Objective: Local control (LC) rate is inversely 
related to the volume and size of the brain metastases 
treated with SRS. We aimed to demonstrate the potential 
role of fSRT with increasing volumes in order to improve LC. 
Materials and Methods: Between 2001-2004, 180 patients 
with brain metastases were treated with stereotactic 
radiosurgery (SRS) or fractionated stereotactic radiotherapy 
(fSRT). Sixty-five percent were treated for newly diagnosed, 
whereas 35% for progressive brain metastases after previous 
whole brain radiotherapy. Median number of metastases was 
2 and distributed as single 43%, 2-3 mets 33%, 4-10 mets 16% 
and >10 mets 8%. Median age was 59 years (29-87 years); 38% 
was female, 62% male. Primary tumor site was lung in 65%, 
breast in 16%, gastrointestinal 7%, kidney 5%, melanoma 2% 
and others 5%. Patients were grouped according to the 
diameter of the largest metastasis as ≤10mm in 15%, 11-
20mm in 36%, 21-30 mm in 31% and >30 mm in 18%. Patient 
fixation was made with thermoplastic masks. CT and MR 
simulation with contrast was made on-site at the same day. 
GTV was equal to PTV. All treatments were performed on 
TrueBeam STx with Novalis (Varian, Palo Alto, USA and 
BrainLAB AG, Feldkirchen, Germany) using flattening filter 
free beams and non-coplanar multiple partial arcs. Decision 
for fractionation was made according to the size of the 
largest metastasis, cumulative volume and location of the 
metastases. Percentage of fSRT in diameters of ≤10mm, 11-
20mm, 21-30 mm and >30 mm were 15%, 57%, 91% and 100%. 
Median peripheral doses were 18 Gy for single fraction (14-20 
Gy), 24 Gy for 3 fractions (18-27 Gy) and 30 Gy for 5 fractions 
(22.5-40 Gy) treatments. 
Results: At a median follow-up of 6 months (1-38 months) 
median overall survival (OS) was 12 months for the whole 
group (newly diagnosed group 13 months, progressive group 8 
months, p=0.004). OS curves separated significantly in 
patients with ≤20mm, 21-30 mm and >30mm diameters with 
median OS as 17, 12 and 7 months, respectively (p<0.01). LC 
at 1 year for the newly diagnosed patients was 79%, and for 
the progressive patients 69% (p<0.01). One-year LC rate for 
≤10mm, 11-20mm, 21-30 mm and >30 mm diameter was 
100%, 74%, 70% and 69%, respectively (p=0.02, for ≤10mm vs 
others). Specifically in the group with large metastases (>30 
mm, n=33) all of whom were treated with fSRT, one-year LC 
rate was 100% for the newly diagnosed patients, and 47% for 
progressive patients. Salvage treatment was performed as 
SRS in 25 patients (14%), WBRT in 7 patients (4%) and surgery 
in 2 patients. Repeat SRS to the same target was done in one 
patient. Radionecrosis was observed in 10 patients (5.6%), 
and all were treated with steroids or bevacizumab without 
surgery. 
Conclusions: Single fraction SRS can achieve high local 
control for small brain metastases. For larger metastases 
fSRT can successfully replace SRS with improved LC and lower 
toxicity. 
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